Invesco Ltd. Boosts Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Invesco Ltd. boosted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 17.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,034,180 shares of the medical research company's stock after buying an additional 151,159 shares during the period. Invesco Ltd. owned approximately 2.02% of Charles River Laboratories International worth $190,910,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in CRL. Versant Capital Management Inc lifted its stake in shares of Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after purchasing an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. increased its holdings in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after purchasing an additional 65 shares in the last quarter. Pilgrim Partners Asia Pte Ltd acquired a new position in Charles River Laboratories International in the 4th quarter worth about $48,000. Tortoise Investment Management LLC grew its position in shares of Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after purchasing an additional 115 shares during the period. Finally, Huntington National Bank increased its position in shares of Charles River Laboratories International by 120.6% during the fourth quarter. Huntington National Bank now owns 300 shares of the medical research company's stock worth $55,000 after purchasing an additional 164 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Morgan Stanley cut their target price on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 5th. Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and upped their target price for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. William Blair cut Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 22nd. Mizuho dropped their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. Finally, Robert W. Baird reduced their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. One research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $182.00.

Charles River Laboratories International Price Performance

NYSE CRL traded up $0.25 on Thursday, reaching $104.50. The company's stock had a trading volume of 411,378 shares, compared to its average volume of 884,916. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The firm has a market cap of $5.13 billion, a PE ratio of 693.77, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $254.15. The business has a 50-day moving average price of $153.13 and a 200 day moving average price of $175.23.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same period in the prior year, the business earned $2.46 earnings per share. Charles River Laboratories International's quarterly revenue was down 1.1% on a year-over-year basis. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster purchased 6,075 shares of the firm's stock in a transaction dated Thursday, February 20th. The stock was bought at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the purchase, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares of the company's stock, valued at $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).